Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572

Watchlist Manager
Zhejiang CONBA Pharmaceutical Co Ltd Logo
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Watchlist
Price: 4.68 CNY -2.09% Market Closed
Market Cap: 11.7B CNY
Have any thoughts about
Zhejiang CONBA Pharmaceutical Co Ltd?
Write Note

Zhejiang CONBA Pharmaceutical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang CONBA Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Cash & Cash Equivalents
ÂĄ1.1B
CAGR 3-Years
5%
CAGR 5-Years
-6%
CAGR 10-Years
5%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
ÂĄ8.8B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
-9%
CAGR 5-Years
3%
CAGR 10-Years
24%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
ÂĄ391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang CONBA Pharmaceutical Co Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.

Intrinsic Value
8.12 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Zhejiang CONBA Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B CNY

Based on the financial report for Sep 30, 2024, Zhejiang CONBA Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 1.1B CNY.

What is Zhejiang CONBA Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%

Over the last year, the Cash & Cash Equivalents growth was -49%. The average annual Cash & Cash Equivalents growth rates for Zhejiang CONBA Pharmaceutical Co Ltd have been 5% over the past three years , -6% over the past five years , and 5% over the past ten years .

Back to Top